Action on Pain

AOP Health, originally founded as AOP Orphan Pharmaceuticals (where the acronym AOP stands for "Action on Pain"), is a leading European pharmaceutical company dedicated to rare diseases and critical care. Headquartered in Vienna, Austria, the company specializes in developing and commercializing integrated therapies in hemato-oncology, cardiology, pulmonology, and intensive care. AOP Health is best known for its flagship product Besremi (ropeginterferon alfa-2b), which is the first interferon approved for the treatment of polycythemia vera. The company manages the entire pharmaceutical value chain, from early-stage research and clinical development to global distribution and patient advocacy. With a strong presence in Europe and the Middle East, AOP Health continues to expand its portfolio through strategic acquisitions and internal R&D. The company rebranded in 2021 to reflect its commitment to providing comprehensive healthcare solutions beyond traditional drug therapy.